Ensysce Biosciences, Inc. (ENSC:NASDAQ) closed at $0.598 on October 15, 2026, up 6.58% on the day. The stock trades 77.5% below its 52-week high of $2.66 and 160.0% above its 52-week low of $0.230. Over the past year, it lost 76.7%. Ensysce Biosciences, Inc. is part of the Finance sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +7.56% | +33.46% | +121.44% | +23.53% | -76.74% |
In 252 trading sessions since October 15, 2025, ENSC closed higher on 107 days (42%). Its best day was February 27, 2026 (+57.72%) and its worst was February 10, 2026 (-27.47%). The stock moved 10% or more in a single session 33 times. It opened at least 5% above the previous day's high 4 times.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost.
Find more stocks like ENSC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.